Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.
Clinical Trials
12
4 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2007
Active, not recruiting
4
33.3%
Completed
2
16.7%
Recruiting
2
16.7%
Terminated
3
25.0%
Withdrawn
1
8.3%
No approval data available
• Viracta Therapeutics has stopped its Phase 2 NAVAL-1 trial for Nana-val in relapsed/refractory EBV+ lymphomas to conserve resources. • The decision to close the trial was not due to safety concerns, but rather to maximize cash runway during a strategic review. • The company is exploring strategic alternatives, including a potential merger, licensing agreement, or sale, to enhance shareholder value. • Viracta will continue assessing Nana-val in a Phase 1b/2 trial for recurrent or metastatic EBV+ nasopharyngeal carcinoma.
• Viracta Therapeutics is developing Nana-Val, an all-oral combination therapy for Epstein-Barr virus (EBV)-associated malignancies, including post-transplant lymphoproliferative disorder (PTLD). • Nana-Val combines nanatinostat, a selective HDAC inhibitor, with valganciclovir, an antiviral agent, to target EBV-infected cells in relapsed/refractory lymphomas. • A pivotal Phase 2 basket trial (NAVAL-1) is ongoing to evaluate Nana-Val in various subtypes of relapsed/refractory EBV+ lymphoma. • The therapeutic landscape for PTLD is evolving, with novel approaches like Nana-Val aiming to improve outcomes for patients with limited treatment options.
